Sobol sensitivity analysis: A tool to guide the development and evaluation of systems pharmacology models

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 2, 2015, Pages 69-79

  Zhang, X Y ^a   Trame, M N ^a   Lesko, L J ^a   Schmidt, S ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARATRIPTAN; SUNITINIB;

AREA UNDER THE CURVE; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DECOMPOSITION; DRUG MECHANISM; EVALUATION STUDY; EVOLUTIONARY ALGORITHM; FACTORIAL DESIGN; FEEDBACK SYSTEM; HOMEOSTASIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; POPULATION MODEL; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMS BIOLOGY; SYSTEMS PHARMACOLOGY MODEL; VOLUME OF DISTRIBUTION; ANIMAL; HUMAN; PHARMACOKINETICS; PHARMACOLOGY; PROCEDURES; REPRODUCIBILITY; SYSTEM ANALYSIS; THEORETICAL MODEL;

ANIMALS; HUMANS; MODELS, THEORETICAL; PHARMACOKINETICS; PHARMACOLOGY; REPRODUCIBILITY OF RESULTS; SYSTEMS BIOLOGY; SYSTEMS INTEGRATION;

EID: 84936757778     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.6     Document Type: Review

References (57)

1. Rogers, M., Lyster, P., &, Okita, R., NIH support for the emergence of quantitative and systems pharmacology. CPT Pharmacometrics Syst. Pharmacol. 2, e37 (2013).
2. del Sol, A., Balling, R., Hood, L., &, Galas, D., Diseases as network perturbations. Curr. Opin. Biotechnol. 21, 566-571 (2010).
3. Kitano, H., Computational systems biology. Nature. 420, 206-210 (2002).
4. Schmidt, S., Post, T.M., Peletier, L.A., Boroujerdi, M.A., &, Danhof, M., Coping with time scales in disease systems analysis: application to bone remodeling. J. Pharmacokinet. Pharmacodyn. 38, 873-900 (2011).
5. Lesko, L.J., Zheng, S., &, Schmidt, S., Systems approaches in risk assessment. Clin. Pharmacol. Ther. 93, 413-424 (2013).
6. van Riel, N.A.W., Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments. Brief. Bioinform. 7, 364-374 (2006).
7. Breimer, D.D., &, Danhof, M., Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe" paradigm. Clin. Pharmacokinet. 32, 259-267 (1997).
8. Danhof, M., de Jongh, J., De Lange, E.C., Della Pasqua, O., Ploeger, B.A., &, Voskuyl, R.A., Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47, 357-400 (2007).
9. Birtwistle, M.R., Hatakeyama, M., Yumoto, N., Ogunnaike, B.A., Hoek, J.B., &, Kholodenko, B.N., Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol. Syst. Biol. 3, 144 (2007).
10. Iyengar, R., Zhao, S., Chung, S.W., Mager, D.E., &, Gallo, J.M., Merging systems biology with pharmacodynamics. Sci. Transl. Med. 4, 126-127 (2012).
11. Zhang, X.Y., Birtwistle, M.R., &, Gallo, J.M., A general network pharmacodynamic model-based design pipeline for customized cancer therapy applied to the VEGFR pathway. CPT Pharmacometrics Syst. Pharmacol. 3, e92 (2014).
12. Jusko, W.J., Moving from basic toward systems pharmacodynamic models. J. Pharm. Sci. 102, 2930-2940 (2013).
13. Benson, N., Metelkin, E., Demin, O., Li, G.L., Nichols, D., &, van der Graaf, P.H., A systems pharmacology perspective on the clinical development of fatty acid amide hydrolase inhibitors for pain. CPT Pharmacometrics Syst. Pharmacol. 3, e91 (2014).
14. Brannmark, C., Nyman, E., Fagerholm, S., Bergenholm, L., Ekstrand, E.M., Cedersund, G., &, Stralfors, P., Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes. J. Biol. Chem. 288, 9867-9880 (2013).
15. Nestorov, I., Graham, G., Duffull, S., Aarons, L., Fuseau, E., &, Coates, P., Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm. Res. 18, 1210-1219 (2001).
16. Freeman, M., Feedback control of intercellular signalling in development. Nature 408, 313-319 (2000).
17. Bhalla, U.S., &, Iyengar, R., Emergent properties of networks of biological signaling pathways. Science 283, 381-387 (1999).
18. Agoram, B., Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models. CPT Pharmacometrics Syst. Pharmacol. 3, e101 (2014).
19. Gutenkunst, R.N., Waterfall, J.J., Casey, F.P., Brown, K.S., Myers, C.R., &, Sethna, J.P., Universally sloppy parameter sensitivities in systems biology models. PLoS Comput. Biol. 3, 1871-1878 (2007).
20. Vanlier, J., Tiemann, C.A., Hilbers, P.A., &, van Riel, N.A., Parameter uncertainty in biochemical models described by ordinary differential equations. Math. Biosci. 246, 305-314 (2013).
21. Benson, N., et al,. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus 3, 20120071 (2013).
22. Sarkar, A.X., &, Sobie, E.A., Quantification of repolarization reserve to understand interpatient variability in the response to proarrhythmic drugs: a computational analysis. Heart Rhythm 8, 1749-1755 (2011).
23. Cummins, M.A., Dalal, P.J., Bugana, M., Severi, S., &, Sobie, E.A., Comprehensive analyses of ventricular myocyte models identify targets exhibiting favorable rate dependence. PLoS Comput. Biol. 10, e1003543 (2014).
24. Saltelli, A., Chan, K., &, Scott, E.M., Sensitivity Analysis: Wiley Series in Probability and Statistics (John Wiley, Chichester, 2000).
25. Kent, E., Neumann, S., Kummer, U., &, Mendes, P., What can we learn from global sensitivity analysis of biochemical systems? PLoS One 8, e79244 (2013).
26. Sahle, S., Mendes, P., Hoops, S., &, Kummer, U., A new strategy for assessing sensitivities in biochemical models. Philos. Trans. R. Soc. A. 366, 3619-3631 (2008).
27. Frey, H.C., &, Patil, S.R., Identification and review of sensitivity analysis methods. Risk Anal. 22, 553-578 (2002).
28. Saltelli, A., Global Sensitivity Analysis: The Primer (John Wiley, Chichester, 2008).
29. Mokhtari, A., &, Frey, H.C., Sensitivity analysis of a two-dimensional probabilistic risk assessment model using analysis of variance. Risk Anal. 25, 1511-1529 (2005).
30. Kiparissides, A., Kucherenko, S.S., Mantalaris, A., &, Pistikopoulos, E.N., Global sensitivity analysis challenges in biological systems modeling. Ind. Eng. Chem. Res. 48, 7168-7180 (2009).
31. Hamby, D.M., A review of techniques for parameter sensitivity analysis of environmental models. Environ. Monit. Assess. 32, 135-154 (1994).
32. Ingalls, B., Sensitivity analysis: from model parameters to system behaviour. Essays Biochem. 45, 177-193 (2008).
33. Zi, Z., Sensitivity analysis approaches applied to systems biology models. IET Syst. Biol. 5, 336-336 (2011).
34. Zi, Z., Zheng, Y., Rundell, A.E., &, Klipp, E., SBML-SAT: a systems biology markup language (SBML) based sensitivity analysis tool. BMC Bioinformatics 9, 342 (2008).
35. Marino, S., Hogue, I.B., Ray, C.J., &, Kirschner, D.E., A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 254, 178-196 (2008).
36. Sobol, I.M., Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates. Math. Comput. Simul. 55, 271-280 (2001).
37. Bentele, M., et al,. Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J. Cell Biol. 166, 839-851 (2004).
38. Blower, S.M., &, Dowlatabadi, H,., Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int. Stat. Rev. 62, 229-243 (1994).
39. Zi, Z., Cho, K.H., Sung, M.H., Xia, X., Zheng, J., &, Sun, Z., In silico identification of the key components and steps in IFN-gamma induced JAK-STAT signaling pathway. FEBS Lett. 579, 1101-1108 (2005).
40. Cho, K.H., Shin, S.Y., Lee, H.W., &, Wolkenhauer, O., Investigations into the analysis and modeling of the TNF alpha-mediated NF-kappa B-signaling pathway. Genome Res. 13, 2413-2422 (2003).
41. Yoon, J., &, Deisboeck, T.S., Investigating differential dynamics of the MAPK signaling cascade using a multi-parametric global sensitivity analysis. PLoS One 4, e4560 (2009).
42. Saltelli, A., Tarantola, S., &, Chan, KPS., A quantitative model-independent method for global sensitivity analysis of model output. Technometrics. 41, 39-56 (1999).
43. Mokhtari, A., Christopher Frey, H., &, Zheng, J., Evaluation and recommendation of sensitivity analysis methods for application to Stochastic Human Exposure and Dose Simulation models. J. Expo. Sci. Environ. Epidemiol. 16, 491-506 (2006).
44. Sobol, I.M., Sensitivity estimates for nonlinear mathematical models. Math. Model. Comp. Exp. 1, 407-414 (1993).
45. Chan, K., Saltelli, A., &, Tarantola, S., Sensitivity analysis of model output: variance-based methods make the difference. Proceedings of the 1997 Winter Simulation Conference, Atlanta, Georgia, USA (1997).
46. Sobol, I.M., On the distribution of points in a cube and the approximate evaluation of integrals. USSR Comp. Math. Math+. 7, 86-112 (1967).
47. Dalal, I.L., Stefan, D., &, Harwayne-Gidansky, J., Low discrepancy sequences for Monte Carlo simulations on reconfigurable platforms. International Conference on Application-Specific Systems, Architectures and Processors, Proceedings, Leuven, Belgium (2008).
48. Houk, B.E., Bello, C.L., Kang, D., &, Amantea, M., A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 15, 2497-2506 (2009).
49. Gueorguieva, I., Nestorov, I.A., Aarons, L., &, Rowland, M., Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan. Pharm. Res. 22, 1614-1626 (2005).
50. Perelson, A.S., Kirschner, D.E., &, De Boer, R., Dynamics of HIV infection of CD4+ T cells. Math. Biosci. 114, 81-125 (1993).
51. Lebedeva, G., et al,. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. Eur. J. Pharm. Sci. 46, 244-258 (2012).
52. Mahdavi, A., Davey, R.E., Bhola, P., Yin, T., &, Zandstra, P.W., Sensitivity analysis of intracellular signaling pathway kinetics predicts targets for stem cell fate control. PLoS Comput. Biol. 3, e130 (2007).
53. Peterson, M.C., &, Riggs, M.M., Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model. CPT Pharmacometrics Syst. Pharmacol. 1, e14 (2012).
54. Peterson, M.C., &, Riggs, M.M., A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 46, 49-63 (2010).
55. de Pillis, L.G., Radunskaya, A.E., &, Wiseman, C.L., A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65, 7950-7958 (2005).
56. Wilkinson, D.J., Stochastic modelling for quantitative description of heterogeneous biological systems. Nat. Rev. Genet. 10, 122-133 (2009).
57. Gowal, S., de Giacomi, M., &, Le Boudec, J.Y., Comment on: a validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 67, 8419-8421; author reply 8420-8411 (2007).